Posted on

Extensively drug-resistant TB (XDR-TB)

Extensively drug-resistant TB (XDR-TB), also known as Extremely Drug-Resistant TB, is emerging as an even more ominous threat. XDR-TB is defined as TB that is resistant to any fluoroquinolone, and at least one of three injectable second-line drugs (capreomycin, kanamycin, and amikacin), in addition to isoniazid and rifampin. This makes XDR-TB treatment extremely complicated, if not impossible, in resource-limited settings.

In a 2006 XDR-TB outbreak in KwaZulu-Natal, South Africa, 52 of 53 people who contracted the disease died within months. It is estimated that 70% of XDR-TB patients die within a month of diagnosis.

The most recent drug-resistance surveillance data issued by the WHO estimates that an average of roughly 5 percent of MDR-TB cases are XDR-TB. Estimating the incidence of XDR-TB is extremely difficult because most laboratories are ill-equipped to detect and diagnose it; it is thought that the majority of XDR-TB cases go undocumented.

Posted on

Multidrug-Resistant Tuberculosis (MDR-TB)

Multidrug-resistant (MDR) tuberculosis is defined as disease caused by strains of Mycobacterium tuberculosis that are at least resistant to treatment with isoniazid and rifampicin; extensively drug-resistant (XDR) tuberculosis refers to disease caused by multidrug-resistant strains that are also resistant to treatment with any fluoroquinolone and any of the injectable drugs used in treatment with second-line anti-tuberculosis drugs (amikacin, capreomycin, and kanamycin). MDR tuberculosis and XDR tuberculosis are serious threats to the progress that has been made in the control of tuberculosis worldwide over the past decade.

The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are major medical and public problem, threatening the global health.

Posted on

Facts about Multidrug-Resistant Tuberculosis (MDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB)

The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are major medical and public problem, threatening the global health.
MDR-TB is defined as TB caused by bacteria that are resistant to at least rifampicin (RMP) and isoniazid (INH) – the two most important first-line anti-TB drugs. The annual global MDR-TB burden is estimated at around 425.000 cases or 5% of the global tuberculosis burden. Multidrug-resistant tuberculosis is a challenge to TB control due to its complex diagnostic and A fast and reliable resistance testing is essential to cut transmission paths and to change treatment to effective antibiotics of the second line. Treatment for MDR-TB is cost-intensive, time-consuming (minimum 18 months) and must be undertaken by a physician experienced in therapy of MDR-TB.

XDR-TB is currently defined as TB caused by bacteria that are resistant to rifampicin and isoniazid as well as resistant to any one of the fluoroquinolones (e.g. ofloxacin and moxifloxacin) and to at least one of the injectable second-line drugs (capreomycin, viomycin, kanamycin or amikacin).

XDR-TB is currently defined as TB caused by bacteria that are resistant to rifampicin and isoniazid as well as resistant to any one of the fluoroquinolones (e.g. ofloxacin and moxifloxacin) and to at least one of the injectable second-line drugs (capreomycin, viomycin, kanamycin or amikacin).

XDR-TB emerges like MDR-TB through mismanagement of treatment. XDR-TB is already spread throughout all regions of the world. In some countries more than 20% of all multidrug-resistant TB cases are XDR.!

GenoType MTBDRplus and GenoType MTBDRsl allow for rapid and reliable detection of MDR/XDR-TB.